₹22.06
−5.89%NSE close, 16 Nov 2026
−47.28%
BALAXI PHARMACEUTICALS is a small cap company, listed on NSE under the symbol BALAXI. At ₹22.06 a share, the market values the whole company at ₹122 crore.
In FY26, it reported sales of ₹270 crore and a net profit of ₹1 crore, an operating margin of 3.2%. Over the last three years, sales fell 7.0% a year and net profit fell 69.2% a year.
The market values the company at 36.1 times its profit over the last twelve months and 0.48 times its book value; its return on equity is 1.3% and its borrowings are 0.20 times its equity.
Promoters hold 65.99% of the shares. Foreign institutions hold 0.00%, and domestic institutions, mutual funds among them, 2.56%.
Over the past year the share price has fallen 47.8%, and it is 48.5% below its 52-week high.
₹ crore. Consolidated figures.
Balaxi Pharmaceuticals Limited Reports Strong Q2 FY27 Performance; Revenue Grows 45%, EBITDA Surges 338% and PAT Rises 450% YoY
Progress of the Company's Pharmaceutical Formulation Plant at Jadcherla, Hyderabad.
Outcome of Board Meeting held on November 12, 2026.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 60.8 | 59.8 | 65.6 | 77.4 | 73.3 | 76.3 | 70.7 | 56.2 | 72.5 | 70.7 | 80.7 | 81.4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 47.1 | 46.4 | 55.5 | 66.8 | 69.3 | 63.7 | 66.6 | 55.0 | 69.5 | 70.6 | 76.0 | 76.3 |
| Operating profit | 13.7 | 13.5 | 10.1 | 10.6 | 4.0 | 12.6 | 4.2 | 1.2 | 3.1 | 0.1 | 4.7 | 5.1 |
| Operating margin | 22.5% | 22.5% | 15.4% | 13.7% | 5.4% | 16.5% | 5.9% | 2.1% | 4.3% | 0.2% | 5.8% | 6.3% |
| Other income | −0.1 | −1.8 | −1.9 | −4.1 | 3.9 | −1.7 | −1.8 | 1.6 | 0.1 | 2.9 | −1.0 | −0.8 |
| Interest | 0.4 | 0.6 | 0.4 | 0.5 | 1.4 | 0.7 | 1.0 | 0.9 | 1.0 | 1.0 | 0.7 | 0.9 |
| Depreciation | 0.5 | 0.7 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.7 | 0.9 | 1.4 |
| Profit before tax | 14.3 | 11.5 | 7.4 | 5.6 | 6.1 | 9.7 | 0.9 | 1.4 | 1.6 | 1.4 | 2.1 | 2.0 |
| Tax | 0.7 | 0.6 | 0.9 | 1.0 | 0.7 | 1.0 | 0.6 | 1.2 | 1.3 | 0.8 | 0.8 | 0.9 |
| Net profit | 13.6 | 10.9 | 6.5 | 4.6 | 5.4 | 8.6 | 0.3 | 0.2 | 0.3 | 0.6 | 1.3 | 1.2 |
| EPS (₹) | 13.29 | 10.41 | 1.17 | 0.84 | 0.97 | 1.56 | 0.05 | 0.04 | 0.06 | 0.11 | 0.24 | 0.21 |
₹ crore, financial years to March.
| Line | FY19 S | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13.6 | 45.6 | 231 | 279 | 336 | 241 | 293 | 270 |
| Expenses | 12.0 | 39.6 | 189 | 229 | 280 | 195 | 255 | 262 |
| Operating profit | 1.6 | 6.1 | 42.4 | 50.2 | 56.5 | 46.7 | 37.2 | 8.5 |
| Operating margin | 12.0% | 13.3% | 18.3% | 18.0% | 16.8% | 19.4% | 12.7% | 3.2% |
| Other income | 0.8 | 2.8 | 2.2 | 5.0 | 2.6 | −2.7 | −3.7 | 2.8 |
| Interest | 0 | 0 | 0.0 | 0.1 | 0.5 | 1.7 | 2.9 | 3.9 |
| Depreciation | 0 | 0.0 | 0.3 | 0.5 | 1.8 | 2.1 | 1.9 | 2.2 |
| Profit before tax | 2.4 | 8.9 | 44.3 | 54.5 | 56.9 | 2.0 | 28.7 | 5.3 |
| Tax | 0.5 | 2.8 | 6.2 | 6.9 | 11.0 | 4.4 | 3.6 | 3.9 |
| Net profit | 2.0 | 6.1 | 37.2 | 47.7 | 48.4 | −2.4 | 25.1 | 1.4 |
| EPS (₹) | 6.47 | 8.12 | 38.14 | 47.66 | 45.86 | -2.69 | 4.54 | 0.26 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 34.1 | −35.0 | −4.5 | 23.0 |
| From investing | −28.5 | −21.8 | −20.8 | −2.8 |
| From financing | −0.2 | 33.9 | 0.4 | −7.7 |
| Spent on fixed assets | −4.8 | −1.4 | −14.9 | −2.4 |
| Free cash flow | 29.4 | −36.4 | −19.4 | 20.6 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 14.5% | 13.4% | 16.1% | 17.1% | 14.4% | -1.0% | 8.6% | 0.5% |
| Operating margin | 12.0% | 13.3% | 18.3% | 18.0% | 16.8% | 19.4% | 12.7% | 3.2% |
| Return on equity | – | – | – | – | 26.4% | -1.2% | 10.8% | 0.6% |
| Return on capital employed | – | – | – | – | 29.5% | 1.7% | 11.2% | 3.0% |
| Return on assets | – | – | – | – | 20.2% | -0.9% | 8.1% | 0.4% |
| Debt to equity | – | – | – | – | 0.06 | 0.09 | 0.22 | 0.22 |
| Interest coverage | – | – | 4,434.00 | 390.40 | 114.90 | 2.20 | 10.80 | 2.40 |
| Debt to assets | – | – | – | – | 0.05 | 0.07 | 0.17 | 0.17 |
| Current ratio | – | – | – | – | 3.64 | 3.88 | 4.45 | 4.04 |
| Quick ratio | – | – | – | – | 1.67 | 2.36 | 3.01 | 2.70 |
| Cash ratio | – | – | – | – | 0.53 | 1.15 | 0.72 | 0.23 |
| Asset turnover | – | – | – | – | 1.40 | 0.93 | 0.94 | 0.80 |
| Fixed asset turnover | – | – | – | – | 20.79 | 16.33 | 20.54 | 5.51 |
| Inventory turnover | – | – | – | – | – | 1.60 | 2.10 | 1.80 |
| Receivables turnover | – | – | – | – | 6.30 | 4.30 | 2.60 | 2.00 |
| Gross margin | – | – | – | – | – | 46.7% | 43.4% | 44.2% |
| Cash from operations to profit | – | – | – | 72.0% | – | – | -140.0% | -317.0% |
| Effective tax rate | 19.3% | 31.2% | 14.0% | 12.6% | 19.3% | 218.9% | 12.6% | 73.3% |
The financial results for the period ended September 30, 2026.
RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended October 2026
RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended September 2026.
RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended August 2026 .
The receipt of WHO-GMP Certification for Company's Pharmaceutical Formulation Manufacturing Facility.
Change in Director(s) of the company.
A copy Srutinizers Report of Annual General Meeting held on 24th August, 2026. Further, the company has informed the Exchange regarding Voting Results.
Proceedings of the 83rd Annual General Meeting held on 24th August, 2026
Corrigendum to Notice of the 83rd Annual General Meeting.
RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended July 2026